Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA

About this update from Jiangsu Recbio Technology Co., Ltd. Class H

Jiangsu Recbio Technology Co Ltd HKEX:2179:NEW DRUG APPLICATION FOR REC610 SHINGLES VACCINE ACCEPTEDAPPLICATION ACCEPTED BY CENTER FOR DRUG EVALUATION, NMPA

View stock analysis, news, and events for Jiangsu Recbio Technology Co., Ltd. Class H